Antibodies

30 Mar 2019 Northern Biologics Reports Initial Phase I Data for MSC-1 at AACR
30 Mar 2019 Forbius’ AVID100, a Novel Anti-EGFR ADC, Reports Positive Phase 1 Data at AACR: Exceptionally High RP2D Established, Phase 2 in SCCHN and sqNSCLC Ongoing
28 Mar 2019 Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
27 Mar 2019 Tizona Announces Initiation of Phase 1/1b Study with Novel Cancer Immunotherapy TTX-030 and First Public Presentation of Pre-Clinical Data with TTX-030 at AACR 2019
27 Mar 2019 Eureka Therapeutics Announces Publication of Preclinical Study Demonstrating GPRC5D as a Promising Target for Antibody-Based Therapies in Multiple Myeloma
26 Mar 2019 Genmab Announces Submission of Supplemental Biologics License Application to FDA for Daratumumab in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma
26 Mar 2019 BioInvent and Transgene extend their collaboration to develop multifunctional oncolytic viruses for the treatment of solid tumors
26 Mar 2019 AbbVie Announces First Regulatory Approval of SKYRIZI™ (risankizumab) for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis in Japan
22 Mar 2019 Genmab Announces European Regulatory Submission for Daratumumab in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma
22 Mar 2019 Initiation Of Phase III Clinical Trial Of BAN2401 In Early Alzheimer's Disease
22 Mar 2019 GSK announces further positive data from DREAMM-1 study of anti-BCMA antibody-drug conjugate in patients with relapsed/refractory multiple myeloma
21 Mar 2019 Momenta Pharmaceuticals Announces Publication of New Data Supporting M281 as First Anti-FcRn Antibody to Inhibit Maternal-Fetal IgG Transfer in the Human Term Placenta
21 Mar 2019 Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease
21 Mar 2019 Innovent Announces First Patient Dosed in a Phase IIa Clinical Study of IBI306, an Anti-PCSK9 Monoclonal Antibody
21 Mar 2019 BioInvent Unveils Broad Anti-TNFR2 Program to Treat Solid Tumors
21 Mar 2019 Data from GARNET study indicates robust activity of dostarlimab in patients with advanced or recurrent endometrial cancer
20 Mar 2019 I-Mab Biopharma Announces Dosing of First Subject in Phase 1 Clinical Trial of Anti-GM-CSF Monoclonal Antibody TJM2 in the United States
20 Mar 2019 Merck KGaA, Darmstadt, Germany, and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer
20 Mar 2019 I-Mab Biopharma and MorphoSys Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma
20 Mar 2019 Tiziana Submits IND Application for Oral Formulation of Foralumab for Treatment of NASH
20 Mar 2019 Aptevo Therapeutics Begins Phase 1 Clinical Trial of APVO210 a Novel Bispecific Antibody for the Treatment of Autoimmune and Inflammatory Diseases
19 Mar 2019 Innovent Announces First Patient Dosed in Phase I Clinical Trial of Anti-CD47 Monoclonal Antibody in the U.S.
19 Mar 2019 Dermira Announces Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis
19 Mar 2019 FDA Approves Genentech’s Tecentriq in Combination With Chemotherapy for the Initial Treatment of Adults With Extensive-Stage Small Cell Lung Cancer
17 Mar 2019 Praluent (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top